Oncology Programs for Development-Stage Monoclonal Antibody Continue
GAITHERSBURG, Md., Aug. 30 /PRNewswire-FirstCall/ -- MedImmune, Inc.
(Nasdaq: MEDI) announced today that it has decided to terminate Phase 2
testing of Vitaxin(R) in patients with rheumatoid arthritis (RA) and psoriasis
based on preliminary data suggesting lack of clinical benefit in these
inflammatory diseases. There were no safety concerns identified in the
preliminary analyses. MedImmune's oncology program for Vitaxin continues to
advance with studies in melanoma and prostate cancer.
Vitaxin targets the alpha-v beta-3 integrin, which is a protein expressed
on the surface of newly forming blood vessels, certain tumor types and on a
number of other cell types, including macrophages and osteoclasts. Based on
preclinical models, the alpha-v beta-3 integrin has been implicated in a
number of disease processes, including the growth and metastasis of tumors,
the bone destruction in RA and the inflammatory process in psoriasis.
About MedImmune, Inc.
MedImmune strives to provide better medicines to patients, new medical
options for physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on the areas of pediatric infectious
diseases, cancer and inflammatory diseases. With approximately 1,800
employees worldwide, MedImmune is headquartered in Maryland. For more
information, visit the company's website at http://www.medimmune.com.
This announcement may contain, in addition to historical information,
certain forward-looking statements that involve risks and uncertainties. Such
statements reflect management's current views and are based on certain
assumptions. Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties discussed in MedImmune's filings with the U.S. Securities and
Exchange Commission. The company is developing several products for potential
future marketing. There can be no assurance that such development efforts
will succeed, that such products will receive required regulatory clearance or
that, even if such regulatory clearance is received, such products will
ultimately achieve commercial success.
SOURCE MedImmune, Inc.
/CONTACT: Media: Jamie Lacey, +1-301-398-4035, or Investors: Peter Vozzo,
+1-301-398-4358 or John Filler, +1-301-398-4086, all of MedImmune, Inc./
/Web site: http://www.medimmune.com /
CO: MedImmune, Inc.
IN: MTC HEA
-- DCM005 --
7619 08/30/2004 09:05 EDT http://www.prnewswire.com